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Abstract 37 
 38 
BCL2A1 is an anti-apoptotic member of the BCL-2 family that contributes to 39 
chemoresistance in a subset of tumors. BCL2A1 has a short half-life due to its 40 
constitutive processing by the ubiquitin-proteasome system. This constitutes a major 41 
tumor-suppressor mechanism regulating BCL2A1 function. However, the enzymes 42 
involved in the regulation of BCL2A1 protein stability are currently unknown. Here we 43 
provide the first insight into the regulation of BCL2A1 ubiquitination. We present 44 
evidence that TRIM28 is an E3 ubiquitin-ligase for BCL2A1. Indeed, endogenous 45 
TRIM28 and BCL2A1 bind to each other at the mitochondria and TRIM28 knock-46 
down decreases BCL2A1 ubiquitination. We also show that TRIM17 stabilizes 47 
BCL2A1 by blocking TRIM28 from binding and ubiquitinating BCL2A1, and that 48 
GSK3 is involved in the phosphorylation-mediated inhibition of BCL2A1 degradation. 49 
BCL2A1 and its close relative MCL1 are thus regulated by common factors but with 50 
opposite outcome. Finally, overexpression of TRIM28 or knock-out of TRIM17 51 
reduced BCLA1 protein levels and restored sensitivity of melanoma cells to BRAF-52 
targeted therapy. Therefore, our data describe a molecular rheostat in which two 53 
proteins of the TRIM family antagonistically regulate BCL2A1 stability and modulate 54 
cell death. 55 
  56 
3 
Introduction 57 
The BCL-2 protein family plays a pivotal role in the regulation of the intrinsic pathway 58 
of apoptosis by controlling the release of cytochrome c from mitochondria and 59 
thereby the activation of caspases [1]. Members of the BCL-2 family fall into pro- or 60 
anti-apoptotic subgroups based on the presence of BCL-2 homology (BH) domains: 61 
in humans the six anti-apoptotic proteins BCL-2, BCL-xL, BCL-B, BCL-w, MCL-1 and 62 
BCL2A1 (also named Bfl-1/A1) contain up to four BH domains while pro-apoptotic 63 
members belong to either the multi-BH containing BAX and BAK or the BH3-only 64 
proteins (e.g. BID, BIM, PUMA). 65 
BCL2A1 is one of the least studied members of the BCL-2 family. In line with its anti-66 
apoptotic activity, BCL2A1 is highly up-regulated in several hematopoietic 67 
malignancies including therapy-resistant B-cell chronic lymphocytic leukemia (B-68 
CLL), acute myeloid leukemia (AML) with poor prognosis and large B-cell lymphomas 69 
[2-7]. Recently, a marked overexpression of BCL2A1, or the amplification of its 70 
transcription factor MITF were shown to correlate with resistance of melanoma cells 71 
to BRAF-directed therapy [8]. Down-regulation of BCL2A1 in most of these 72 
malignancies restores sensitivity to chemotherapeutics, providing a clear therapeutic 73 
rationale for targeting BCL2A1 in cancer [8-10]. Structure-based medicinal chemistry 74 
has generated small molecule inhibitors tailored to specifically bind the BH3-binding 75 
cleft of anti-apoptotic BCL-2 proteins, blocking their survival activity and restoring the 76 
sensitivity of cancer cells towards apoptosis. To date, this strategy has not provided 77 
inhibitors of BCL2A1, possibly because of the atypical shape of BCL2A1 hydrophobic 78 
groove which sequesters a restricted spectrum of BH3-only proteins, namely NOXA, 79 
PUMA and BIM [11-13]. Moreover, in some cases, resistance to these BH3 mimetics 80 
developed by cancer cells involves de novo synthesis of BCL2A1 protein [14-16]. 81 
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BCL2A1 is characterized by a short half-life which limits its intrinsic pro-survival 82 
activity [17, 18], a characteristic shared with its two closest relatives MCL-1 and BCL-83 
B [19]. Importantly, reducing ubiquitin-proteasome-mediated degradation of BCL2A1 84 
favors tumor formation in vivo [20]. BCL2A1 differs from other pro-survival BCL-2 85 
proteins in that it contains a C-terminal helix phylogenetically unrelated to that found 86 
in other BCL-2 homologues [21] which does not fulfill the criteria of a typical 87 
transmembrane domain [22-24]. Interestingly this C-terminal segment shows features 88 
of a degron as it regulates BCL2A1 stability and includes lysine residues critical for 89 
BCL2A1 ubiquitination and degradation by the proteasome [17, 18, 20]. In addition, 90 
phosphorylation of crucial residues within the degron impairs both ubiquitination and 91 
degradation of BCL2A1 [18, 20]. Whereas the identification of several protein 92 
kinases, E3 ubiquitin-ligases and a deubiquitinase (DUB) of MCL-1 fueled intense 93 
efforts to design compounds aimed at inducing proteasomal degradation of MCL-1 94 
[25, 26], the key determinants that regulate the ubiquitination and degradation of 95 
BCL2A1 remain unknown. 96 
Here, we present evidence that TRIM28 is an E3 ubiquitin-ligase for BCL2A1. We 97 
also describe the existence of a “molecular rheostat” in which TRIM17 inhibits the 98 
ubiquitination and proteasomal degradation of BCL2A1 induced by TRIM28. 99 
Importantly, overexpression of TRIM28 or downregulation of TRIM17 reduced the 100 
protein level of BCLA1 and restored sensitivity to BRAF-targeted therapy in 101 
melanoma cells that exhibit a survival dependency on BCL2A1. Last, our data 102 
suggest that GSK3 is involved in the inhibition of BCL2A1 degradation. 103 
 104 
 105 
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Results 106 
 107 
TRIM28 as the first E3 ubiquitin-ligase of BCL2A1 to be identified 108 
In order to identify the E3 ubiquitin-ligases that induce poly-ubiquitination of BCL2A1, 109 
we searched for binding partners of BCL2A1. Endogenous proteins from HEK293T 110 
cells co-immunoprecipitating specifically with GFP-tagged BCL2A1 were separated 111 
by SDS-PAGE and analyzed by mass spectrometry. A ∼110 kDa band corresponded 112 
to TRIM28 in GFP-BCL2A1-expressing cells but not in control GFP-expressing cells 113 
(Fig. 1a and Fig. S1a). Co-immunoprecipitation experiments confirmed that TRIM28 114 
does interact with BCL2A1. Indeed, GFP-Trap beads precipitated HA-TRIM28 115 
together with GFP-BCL2A1, with a marked preferential interaction of TRIM28 with the 116 
phosphorylation defective mutant BCL2A1(S152A,T156A), compared with wild type 117 
BCL2A1 (Fig. 1b, upper panel). This mutant has been previously shown to be highly 118 
ubiquitinated and labile [18, 20]. Reciprocal co-immunoprecipitations using HA-Trap 119 
beads further corroborated a physical association of these two proteins (Fig. 1b, 120 
lower panel). Then, we conducted in situ proximity ligation assay (PLA) in the SK-121 
MEL-28 melanoma cell line that expresses high levels of endogenous BCL2A1. 122 
Close proximity was detected between endogenous TRIM28 and endogenous 123 
BCL2A1 proteins, as assessed by a PLA signal which increased following ectopic 124 
expression of Flag-BCL2A1 (Fig. S1b) and was abolished when BCL2A1 gene 125 
expression was impaired by an inducible CRISPR/Cas9 system (Fig. 1c). As BCL2A1 126 
is a mitochondrial protein and TRIM28 is mainly nuclear, we examined the subcellular 127 
localization of the interaction between the two endogenous proteins in HuH7 128 
hepatocarcinoma cells. Our PLA data strongly suggest that they interact mainly at the 129 
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level of mitochondria (Fig. 1d). Taken together, these results indicate that a 130 
mitochondrial pool of TRIM28 forms complexes with BCL2A1. 131 
We next examined whether TRIM28 functions as a bona fide BCL2A1 E3 ubiquitin-132 
ligase. As previous studies showed that TRIM28 E3 ubiquitin-ligase activity can be 133 
modulated by MAGE proteins [27, 28], we measured the ubiquitination level of 134 
BCL2A1 in HEK 293T cells which do not express endogenous MAGE proteins [27]. 135 
Interestingly, BCL2A1 ubiquitination was strongly stimulated in the presence of 136 
TRIM28 regardless of MAGE-C2 co-expression (Fig. 2a). More importantly, depletion 137 
of endogenous TRIM28 by two independent siRNAs both strongly decreased the 138 
polyubiquitination of ectopically expressed BCL2A1 in HEK cells (Fig. 2b) and 139 
increased the protein level of endogenous BCL2A1 in SK-MEL-28 cells (Fig. 2c). In 140 
addition, we measured the half-life of Flag-BCL2A1, with or without co-transfected 141 
TRIM28. Notably, wild type TRIM28, but not the inactive TRIM28(C65A/C68A) RING 142 
mutant, induced a two-fold decrease in Flag-BCL2A1 half-life (Fig. 2d) indicating that 143 
TRIM28 stimulates BCL2A1 protein degradation. Moreover, this effect depends on 144 
the presence of a valid RING domain responsible for the E3 ubiquitin-ligase activity of 145 
TRIM28. Altogether, these results strongly suggest that TRIM28 is an E3 ubiquitin-146 
ligase for BCL2A1 involved in the regulation of its stability.  147 
 148 
TRIM17 enhances BCL2A1 stability by inhibiting TRIM28-mediated 149 
ubiquitination of BCL2A1 150 
We have previously shown that TRIM17 is an E3 ubiquitin-ligase for MCL-1, the 151 
closest phylogenetic homologue of BCL2A1 [21, 29]. To test whether TRIM17 could 152 
also modulate BCL2A1 stability, we first examined whether TRIM17 binds BCL2A1. 153 
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Co-immunoprecipitation experiments showed a significant interaction between both 154 
ectopically expressed (Fig. 3a) and endogenous (Fig. 3b) TRIM17 and BCL2A1 155 
proteins. Then, we co-expressed Flag-BCL2A1 along with increasing amounts of 156 
GFP-TRIM17 plasmid. Surprisingly, Flag-BCL2A1 significantly accumulated as 157 
TRIM17 expression increased (Fig. 3c). This accumulation was due to a stabilization 158 
of BCL2A1, as TRIM17 expression led to an increase in Flag-BCL2A1 half-life (Fig. 159 
3d). 160 
To gain insights into the mechanism of BCL2A1 stabilization by TRIM17, we first 161 
tested whether TRIM17 could bind TRIM28. Indeed, TRIM17 exhibited a strong 162 
interaction with TRIM28 as determined by co-immunoprecipitation of ectopically 163 
expressed proteins (Fig. 4a), and the detection of a specific PLA signal between the 164 
two endogenous proteins in SK-MEL-28 cells (Fig. 4b). Then, we co-expressed the 165 
three partners, BCL2A1, TRIM28 and TRIM17 and checked for the presence of TRIM 166 
proteins in BCL2A1 immunoprecipitates. Interestingly, TRIM17 completely abrogated 167 
the interaction between BCL2A1 and TRIM28 whereas the TRIM17/BCL2A1 168 
interaction was preserved in the presence of TRIM28 (Fig. 4c). Moreover, ectopic 169 
expression of TRIM17 strongly reduced poly-ubiquitination of BCL2A1 induced by 170 
TRIM28 (Fig. 4d). Taken together, these results suggest that TRIM17 stabilizes 171 
BCL2A1 by inhibiting TRIM28-mediated ubiquitination of BCL2A1, most probably by 172 
preventing the physical interaction between BCL2A1 and its E3 ubiquitin-ligase (Fig. 173 
4e). 174 
 175 
TRIM17/TRIM28 as a molecular rheostat modulating the survival function of 176 
BCL2A1 in melanoma cells 177 
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We next focused on TRIM17/TRIM28 antagonistic functions on BCL2A1 stability as a 178 
possible determinant of chemoresistance in human cancers. Previous studies 179 
demonstrated that BCL2A1 is frequently amplified in melanoma tumors and that its 180 
overexpression promotes tumorigenesis and resistance to several apoptosis-inducing 181 
drugs including some of the clinically approved BRAF inhibitors [8, 30]. Our real-time 182 
RT-PCR data show that TRIM17 and TRIM28 are expressed in SK-MEL-5 and SK-183 
MEL-28, two cell lines harboring a BRAF(V600E) mutation and high BCL2A1 184 
expression [8] (Fig.5a), with a more robust expression in SK-MEL-28 cells (Fig. 5a). 185 
Strikingly, a reduction of BCL2A1 mRNA levels by half using a specific siRNA (Fig. 186 
5b) induced a strong sensitization of SK-MEL-28 cells to the BRAF inhibitor 187 
PLX4720, with a two-fold increase in apoptotic cells (Fig. 5c). Altogether, these 188 
results establish a clear link between BRAF inhibitor resistance and BCL2A1 189 
expression in SK-MEL-28 cells and define these cells as an appropriate model to 190 
study the effect of the TRIM17/TRIM28 balance on BCL2A1 expression and pro-191 
survival activity. 192 
To address this latter issue, SK-MEL-28 cells were transfected with GFP-tagged 193 
versions of TRIM17 and TRIM28. Consistent with our data showing that TRIM28 194 
accelerates BCL2A1 degradation (Fig. 2), overexpression of TRIM28, but not of its 195 
inactive RING mutant (C65A/C68A), decreased the protein level of endogenous 196 
BCL2A1 (Fig. 5d). In contrast, TRIM17 overexpression resulted in BCL2A1 197 
accumulation (Fig. 5d), in agreement with TRIM17-mediated stabilization of BCL2A1 198 
(Fig. 3c,d). Moreover, TRIM28 overexpression induced an increased sensitivity of 199 
SK-MEL-28 cells towards PLX4720-mediated apoptosis, whereas its inactive RING 200 
mutant had no effect (Fig. 5e, Fig. S2). Interestingly, mRNA levels of TRIM17 showed 201 
a 4-fold increase in SK-MEL-28 cells treated with PLX4720 (Fig. 5f), correlating with 202 
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an accumulation of BCL2A1 protein (Fig. 5g). Therefore, it is tempting to hypothesize 203 
that TRIM17 induction may participate in chemoresistance to PLX4720 by inhibiting 204 
TRIM28-mediated elimination of BCL2A1.  205 
To test this hypothesis, we used an inducible CRISPR/Cas9 system [31] to induce 206 
efficient and temporally controlled depletion of TRIM17 or BCL2A1 in SK-MEL-28 207 
cells (Fig. 6a). This system consists in two lentiviral vectors, one allowing a 208 
constitutive expression of Cas9-T2A-mCherry and the other allowing both 209 
doxycycline-inducible expression of specific single guide RNA (sgRNA) and 210 
constitutive expression of the tetracycline repressor and eGFP protein [31]. Two 211 
different sgRNAs targeting TRIM17 (sgTRIM17#1 and #2), one sgRNA against 212 
BCL2A1 (sgBCL2A1) [32] and one negative control sgRNA (targeting mouse Bim) 213 
were used. Doubly transduced SK-MEL-28 cells were selected by fluorescence-214 
activated cell sorting (FACS) based on mCherry and eGFP expression (Fig. S3). As 215 
expected, following a 72 h doxycycline treatment, InDels (insertions and deletions of 216 
bases in the genomic DNA) were detected in exon 1 of the TRIM17 locus with both 217 
sgTRIM17#1 and sgTRIM17#2 by using the T7E1 assay (Fig. 6b) and next-218 
generation sequencing (Fig. S4a) [31]. Doxycycline treatment resulted in an average 219 
of 72% mutation rates with sgTRIM17#1, 39% with sgTRIM17#2 and up to 95% with 220 
sgBCL2A1, whereas no InDels were detected at TRIM17 or BCL2A1 loci using the 221 
negative control sgRNA (Fig. S4). Importantly, depletion of endogenous TRIM17 222 
using this system increased the number of PLA dots, measuring the close proximity 223 
between endogenous TRIM28 and BCL2A1, in SK-MEL-28 cells (Fig. 6c), further 224 
supporting the notion that TRIM17 restricts the TRIM28/BCL2A1 interaction. As 225 
expected, expression of sgBCL2A1 induced a strong depletion of BCL2A1 protein 226 
(Fig. 6d). Importantly, expression of the two independent sgRNA targeting TRIM17 227 
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also reduced BCL2A1 protein level (Fig. 6e) without affecting its mRNA level (Fig. 228 
S5a), thereby supporting the idea that endogenous TRIM17 regulates BCL2A1 at the 229 
post-translational level. 230 
To examine whether TRIM17 plays a role in chemoresistance, we assessed the 231 
sensitivity of SK-MEL-28 cells to PLX4720 following induction of the different 232 
sgRNAs. As previously shown with RNA interference (Fig. 5b,c), PLX4720 rapidly 233 
induced apoptosis in sgBCL2A1-expressing cells (Fig. 6f). Importantly, induction of 234 
the two sgRNAs targeting TRIM17 significantly sensitized melanoma cells to 235 
PLX4720 treatment (Fig. 6f). In contrast, treatment with doxycycline alone did not 236 
trigger any cell death in sgTRIM17 and sgBCL2A1-transduced SK-MEL-28 cells for 237 
up to 72 h (Figure S5b). Therefore, our data indicate that alteration of TRIM17 238 
expression both reduces BCL2A1 protein levels and sensitizes melanoma cells to 239 
BRAF-directed therapy.  240 
 241 
Role of the protein kinase GSK3 in the regulation of BCL2A1 stability 242 
In contrast to our previous identification of TRIM17 as an E3 ubiquitin-ligase for MCL-243 
1 [29], our present data suggest that TRIM17 counteracts BCL2A1 ubiquitination, 244 
although both proteins are the closest homologues among anti-apoptotic members of 245 
the BCL-2 family. Likewise, GSK3-induced phosphorylation promotes MCL-1 246 
ubiquitination and degradation [33], whereas phosphorylation of BCL2A1 C-terminal 247 
alpha-9 helix prevents its protein decay [18, 20]. Consistently, the phosphorylation 248 
defective mutant BCL2A1(S152A,T156A), that is highly ubiquitinated and very 249 
unstable [18, 20] interacts more strongly with TRIM28 compared with wild type 250 
BCL2A1 (Fig. 1b). Given the opposite effect of TRIM17 and phosphorylation on 251 
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BCL2A1 and MCL-1, and as GSK3 is a protein kinase for MCL-1, we examined 252 
whether GSK3 could also regulate BCL2A1 stability. 253 
First, we found that the highly conserved serine 152 within the α9 degron sequence 254 
of BCL2A1 was predicted to be a GSK3 consensus site (Fig. 7a). Consistently, a 255 
synthetic peptide derived from the α9 helix of BCL2A1 (BCL2A1-α9) was 256 
phosphorylated in vitro with recombinant GSK3 (Fig. 7b). In contrast, no increase in 257 
phosphorylation was observed in vitro when the full-length GST-tagged BCL2A1(1-258 
175) protein and GSK3 were incubated together (Fig. S6). However, according to a 259 
three-dimensional structure model, full-length BCL2A1(1-175) may adopt two distinct 260 
conformational states: one with the C-terminal helix α9 located within the 261 
hydrophobic BH3-binding cleft and one with the helix α9 freely accessible [34]. Based 262 
on this model, we reasoned that a BH3 peptide able to interact with the hydrophobic 263 
groove of BCL2A1 would dislodge the helix α9 from the groove and would thus 264 
expose its phosphorylation-prone residues. Therefore, we performed in vitro 265 
phosphorylation following pre-incubation of full-length GST-BCL2A1 with different 266 
BH3 peptides. Under these conditions, a strong GSK3-mediated phosphorylation of 267 
BCL2A1 was detected with BH3 peptides from NOXA and PUMA, which are known 268 
to interact with BCL2A1, whereas neither a murine NOXA- nor a BAD-derived BH3 269 
peptide, both known to have poor affinity for BCL2A1 [11, 13], were able to facilitate 270 
GSK3-mediated phosphorylation of BCL2A1 (Fig. 7c).  271 
To further examine whether endogenous GSK3 could influence BCL2A1 stability in 272 
cells, we used an interleukin-3 (IL-3)-dependent FL5.12 cell line stably expressing 273 
GFP-BCL2A1. IL-3 withdrawal is known to induce a strong GSK3 activation in FL5.12 274 
cells [33]. Consistently, we found a substantial stabilization of BCL2A1 following IL-3 275 
withdrawal (Fig. 7d), when GSK3 was activated (Fig. 7e). In contrast, BCL2A1 protein 276 
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half-life was not significantly different from the control condition when the cells were 277 
deprived of IL-3 in the presence of a specific GSK3 inhibitor (Fig. 7d). Altogether, 278 
these data suggest that GSK3 is involved in the phosphorylation-mediated 279 
stabilization of BCL2A1.  280 
 281 
  282 
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Discussion 283 
TRIM proteins that represent the largest class of RING-containing E3 ubiquitin-284 
ligases [35], have various functions in cellular processes including apoptosis, 285 
autophagy, innate immunity and carcinogenesis [36]. In the present study, we 286 
describe a molecular rheostat in which two TRIM proteins antagonistically regulate 287 
the ubiquitin-mediated degradation of BCL2A1, thereby modulating cell death. 288 
Indeed, we present several lines of evidence indicating that TRIM28 is an E3 289 
ubiquitin-ligase for BCL2A1 that favors its degradation. Notably, overexpression of 290 
TRIM28 increased the ubiquitination level of BCL2A1 and decreased its half-life. 291 
More importantly, silencing of TRIM28 decreased the ubiquitination level of BCL2A1, 292 
indicating that endogenous TRIM28 participates in BCL2A1 ubiquitination. 293 
Interestingly, B-cell specific TRIM28 KO mice display impaired B-cell maturation 294 
similar to that observed in transgenic mice overexpressing BCL2A1 in B-cells [37, 295 
38]. As BCL2A1 is predominantly expressed within the hematopoietic lineage, where 296 
it plays a crucial role in B-cell maturation [23], these similar phenotypes suggest that 297 
impairing TRIM28 or overexpressing BCL2A1 has the same effect in B cells and 298 
further support the idea that TRIM28 regulates the protein level of BCL2A1.  299 
As a predominantly nuclear protein, TRIM28 is known to regulate biological functions 300 
through transcriptional co-repression activity in association with heterochromatin-301 
associated protein 1 (HP1) [39]. However, TRIM28 has also been described as a 302 
SUMO- or ubiquitin-ligase which can modify both nuclear and cytoplasmic proteins 303 
[27, 28, 40-42]. Consistently, our present findings indicate that the interaction 304 
between TRIM28 and BCL2A1 occurs mainly at the level of the mitochondria, 305 
suggesting that TRIM28 mediates BCL2A1 ubiquitination outside of the euchromatin 306 
context. 307 
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By inducing the ubiquitination and degradation of the prosurvival factor BCL2A1, 308 
TRIM28 may have an anti-tumoral activity in cancer cells whose survival depends on 309 
a high expression of BCL2A1. Consistently, liver-specific depletion of TRIM28 310 
provokes hepatocarcinoma formation in mice [43]. In addition, TRIM28 has been 311 
shown to suppress the activity of the oncogenic transcription factors HIF-1α and 312 
STAT3 [44, 45], and to de-repress the transcription of major pro-apoptotic genes of 313 
the BCL-2 family including BAX, PUMA and NOXA [46]. Conversely, TRIM28 level 314 
has been linked to poor prognosis in gastric cancer and thyroid carcinoma [47-49] 315 
and TRIM28 has been reported to ubiquitinate and eliminate p53 and AMPK, two 316 
factors that participate in tumor suppression [27, 28]. However, in the latter cases, 317 
the E3-ubiquitin ligase activity of TRIM28 requires the presence of MAGE cofactors 318 
[50], which is not the case for TRIM28-mediated ubiquitination of BCL2A1.  319 
Our results further show that TRIM17 inhibits TRIM28-mediated ubiquitination of 320 
BCL2A1 and induces its stabilization. We propose a mechanism in which TRIM17 321 
leads to the disruption of the TRIM28/BCL2A1 complex, thereby preventing the 322 
interaction between the E3 ubiquitin-ligase and its substrate. One possibility is that 323 
TRIM17 forms an inactive hetero-oligomer with TRIM28 that cannot bind BCL2A1. 324 
Indeed, we found that TRIM17 strongly interacts with TRIM28. Recent structural 325 
studies suggest that homo-oligomerization of TRIM proteins is crucial for their 326 
catalytic activity [51]. Therefore, it is tempting to speculate that formation of 327 
TRIM17/TRIM28 hetero-oligomers, at the expense of TRIM28 homo-oligomerization, 328 
prevents the E3 ubiquitin-ligase activity of TRIM28 and its interaction with BCL2A1. 329 
Alternatively, TRIM17 may compete with TRIM28 to bind BCL2A1. Indeed, we also 330 
found that TRIM17 is able to co-immunoprecipitate with BCL2A1. These two 331 
possibilities are not mutually exclusive and are in agreement with previous reports 332 
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showing that TRIM proteins can both bind an E3-ubiquitin ligase and its substrate to 333 
prevent ubiquitination [52]. 334 
We have previously found that TRIM17 gene expression is upregulated early during 335 
neuronal apoptosis [53] and following different cellular stresses (unpublished results). 336 
Notably, TRIM17 is induced following treatment of melanoma cells with the anti-337 
cancer drug PLX4720. Therefore, TRIM17 induction may participate in 338 
chemoresistance, but also in tumorigenesis in cells undergoing chronic stress, by 339 
increasing BCL2A1 levels. Importantly, we have previously identified TRIM17 as an 340 
E3 ubiquitin-ligase for the anti-apoptotic protein MCL-1 in neurons [29]. Our present 341 
data thus suggest that TRIM17 may yield opposite effects in tissues concomitantly 342 
expressing the two pro-survival factors relatives MCL-1 and BCL2A1, by inducing the 343 
simultaneous down-regulation of MCL-1 and stabilization of BCL2A1. Our study 344 
further broadens this dichotomy by showing that GSK3-mediated phosphorylation of 345 
BCL2A1 prevents its degradation, whereas it is well documented that MCL-1 346 
phosphorylation by GSK3 favours its protein decay [26, 33]. The current paradigm 347 
presents GSK3 as a pro-apoptotic protein as its expression induces cell death in 348 
neuronal and hematopoietic cells and GSK3 inhibitors protect neurons from 349 
apoptosis [29, 54-56]. Nevertheless, GSK3 expression has also been shown to have 350 
a protective function in liver cells [57]. This paradox could be resolved by the 351 
opposite effects that GSK3 can exert on anti-apoptotic proteins of the BCL-2 family, 352 
i.e. accumulation for BCL2A1 and degradation for MCL-1. 353 
Although phylogenetically close, BCL2A1 differs from MCL-1 by its α9 C-terminal 354 
helix which is identical to a 28 amino acid stretch from the phylogenetically unrelated 355 
tumor suppressor protein HCCS-1 [22]. The duplication of this HCCS-1 sequence 356 
conferred a degron-like feature to BCL2A1 [17, 20]. Importantly, since HCCS-1 is 357 
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believed to be pro-apoptotic, it is conceivable that this duplication event incidentally 358 
brought GSK3-mediated stabilization to BCL2A1 while it originally stabilized a pro-359 
apoptotic protein. Yet, beyond these differences, BCL2A1 and MCL-1 do not share a 360 
similar pattern of tissue expression. Therefore, TRIM17 may have a pro-apoptotic 361 
effect in neurons where MCL-1 expression is crucial for survival and have an 362 
opposite anti-apoptotic effect in cell types expressing BCL2A1. Interestingly, 363 
extensive observations of transcriptional patterns underscore that MCL-1 mRNA 364 
levels are inversely correlated with BCL2A1 expression in melanoma. Notably, SK-365 
MEL-28 cells which show high levels of BCL2A1, express almost no MCL-1 [8]. This 366 
may explain why depletion of TRIM17, using an inducible CRISPR/Cas9 system in 367 
these cells, restored their sensitivity to PLX4720-induced apoptosis, in a similar way 368 
as BCL2A1 silencing or TRIM28 overexpression. Our data thus provide a rationale 369 
for targeting TRIM17 to promote BCL2A1 degradation in order to restore sensitivity of 370 
BCL2A1-dependent cancer cells towards chemotherapeutics. 371 
In contrast to MCL-1, which is necessary for the survival of a myriad of cell lineages 372 
[58], BCL2A1 is not indispensable for cell survival in normal physiology. Indeed, 373 
BCL2A1 knock-out mice show only minor defects in the hematopoietic compartment 374 
[59, 60]. Recent data also suggest that BCL2A1 plays a redundant role with BCL-2 375 
and MCL-1 to maintain survival of immune cells [61]. Therefore, therapeutic targeting 376 
of BCL2A1 is expected to induce less deleterious side effects than MCL-1 targeting. 377 
Our present study provides the first insight into the regulation of BCL2A1 378 
ubiquitination by identifying TRIM28 as one of its E3 ubiquitin-ligases, TRIM17 as a 379 
regulator of TRIM28 and GSK3 as a protein kinase regulating BCL2A1 stability. As 380 
such, our results may pave the road for the development of novel therapeutic 381 
17 
strategies aiming at specifically down-regulating BCL2A1 in cancers that express 382 
abnormally high levels of this pro-survival protein. 383 
  384 
18 
Materials and Methods 385 
 386 
Cell culture 387 
SK-MEL-28, SK-MEL-5, HEK293T, HuH7, cell lines were grown in high-glucose 388 
DMEM supplemented with 10% calf serum (FCS) (PAA), 100U/ml penicillin, 100 389 
μg/ml streptomycin (Gibco) and 2 mM L-Glutamine. 390 
Mouse WEHI-3B cells and the IL3-dependent mouse FL5.12 pro-B cells were 391 
maintained in RPMI-1640 medium (Sigma) supplemented with 10% fetal calf serum 392 
(FCS), 20 mM HEPES, 2 mM L-glutamine, penicillin (100 U/ ml) and streptomycin 393 
(100 μg/ml). The culture medium for FL5.12 cells was supplemented with 10% 394 
supernatant from confluent WEHI-3B cell cultures as a source of IL-3. FL5.12 cells 395 
stably expressing GFP-BCL2A1 were generated as previously described [18] and 396 
were maintained in the presence of G418 (1 μg/ml) (Gibco). 397 
 398 
Constructs, transfection and siRNAs 399 
BCL2A1 cDNA sequence was synthesized by Genecust and subcloned in pFLAG-400 
CMV2 (Sigma).  401 
The cDNAs of human TRIM28, C-terminally fused to Myc tag in pCDNA3 MycS1 RfC 402 
or N-terminal fused to GFP in pEGFP plasmid-N1, were obtained from the ORFeome 403 
library (Montpellier Genomic Collection-MGC facility). Myc- and GFP-tagged 404 
C65A/C68A RING mutants of TRIM28 were generated using Quickchange Site-405 
Directed Mutagenesis Kit (Agilent) and were a gift of Véronique Baldin (CRBM, 406 
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Montpellier). pKH3-TRIM28 plasmid expressing HA-tagged TRIM28 was obtained 407 
from Addgene. 408 
Cells were transfected with GenJet™ in vitro transfection reagent (Ver. II) (SignaGen 409 
laboratories, Ijamsville, MD), with Lipofectamine 2000 (Invitrogen) or Lipofectamine 410 
3000 (for SK-MEL-28 cells) according to the manufacturer’s instructions.  411 
siRNAs transfection was performed using Lipofectamine RNAiMAX (Invitrogen) 412 
according to the manufacturer’s protocol. The sequences of the siRNAs used were 413 
as follows: siLuciferase (5’-UAUCCUCACAGCUAGUGCAGCACUGdTdT-3’), 414 
siTRIM28 3’UTR (5'-ACAGGACAGAGAACAGAGCdTdT-3'), siTRIM28 ORF (5'-415 
UCGAAGUAUUCCGCGUACGdTdT-3'), siBCL2A1 (5’-416 
GUUUGAAGACGGCAUCAUdTdT-3’). 417 
 418 
Mass spectrometry 419 
GFP-BCL2A1, or GFP as a control, was transiently expressed in HEK293T cells and 420 
immunoprecipitated using GFP-Trap system (Chromotek) in lysis buffer (50 mM Tris-421 
HCl [pH 7.5], 150 mM NaCl, 0.5% NP-40 and protease inhibitor cocktail). Beads were 422 
washed four times in 50 mM Tris-HCl [pH 7.5], supplemented with 0.5 M NaCl and 423 
protease inhibitor cocktail. Eluted proteins were separated by SDS-PAGE and 424 
stained with coomassie blue. The band excised from the gel was subjected to 425 
reduction, carbamidomethylation and tryptic digestion. Peptide sequences were 426 
determined by mass spectrometry using a LTQ Velos instrument (Dual Pressure 427 
Linear Ion Trap) equipped with a nanospray source (Thermo Fisher Scientific) and 428 
coupled to a U3000 nanoLC system (Thermo Fisher Scientific). A MS survey scan 429 
was acquired over the m/z range 400-1600 in Enhanced resolution mode. The data 430 
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dependent MS/MS scans were acquired in normal resolution mode over the m/z 431 
range 65-2000 for the 20 most intense MS ions with a charge of 2 or more and with a 432 
collision energy set to 35eV. The spectra were recorded using dynamic exclusion of 433 
previously analyzed ions for 0.5 min with 50 millimass units (mmu) of mass tolerance. 434 
The peptide separation was obtained on a C18 PepMap micro-precolumn (5 μm; 100 435 
Å; 300 μm x 5 mm; Dionex) and a C18 PepMap nanocolumn (3 μm; 100 Å; 75 μm x 436 
150 mm; Dionex) using a linear 60 min gradient from 0 to 50% B, where solvent A 437 
was 0.1% HCOOH in H2O/CH3CN (95/5) and solvent B was 0.1% HCOOH in 438 
H2O/CH3CN (20/80) at 300 nL/min flow rate. Proteins identification was performed 439 
with the MASCOT algorithm (v2.2 Matrix Science) through the Proteome Discoverer 440 
software (v1.1 Thermo Fisher Scientific) against the Swiss-Prot Human database 441 
[UniProtKB/Swiss-Prot Release 2012_12]. 442 
 443 
BCL2A1 half-life measurement and western blot analysis 444 
To measure the half-life of BCL2A1, cells were transfected with the indicated 445 
plasmids for 24 h and 10 μg/mL cycloheximide was added to the medium for 446 
increasing times before cell lysis and protein extraction, in order to block protein 447 
synthesis and to follow the degradation of BCL2A1 with time by immunoblot. 448 
Total protein extracts were prepared from cell lines by lysis in RIPA buffer (25 mM 449 
Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 0.1% SDS, 1% sodium deoxycholate) 450 
supplemented with protease inhibitor cocktail (Roche). Protein extracts were 451 
quantified using BCA assay (Pierce), separated by 4-12% SDS-PAGE and 452 
transferred onto PVDF membranes using iBlot2 system (Invitrogen). Blocking, 453 
probing with antibodies and chemoluminescent visualization of immunoreactive 454 
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proteins were performed as previously described [53]. Antibodies used for detection 455 
of proteins were the following: GFP (Torrey Pines #TP401), Flag (Sigma, clone M2), 456 
HA (Roche, clone 3F10), BCL2A1 (Millipore, #ABC498), TRIM28 (Abcam, 457 
#ab10482), tubulin (Sigma, clone DM1A #T6199), GSK3 (cell signaling, clone 458 
D5C5Z), phosphor-Ser9 GSK3 (cell signaling, clone 5B3), vinculin (Santa-cruz #SC-459 
55465). ). ImageJ software was used for optical density quantitation of western blots. 460 
 461 
Co-Immunoprecipitation 462 
Following transfection with the indicated plasmids for 24 h, HEK293T cells were 463 
homogenized in lysis buffer A (50 mM Tris-HCl [pH 7.5], 150 mM NaCl; 0.5 mM 464 
EDTA and protease inhibitor cocktail) containing 1% NP-40 for immunoprecipitation 465 
with anti-FlagM2 beads (Sigma) and 0.5% NP-40 for immunoprecipitation with GFP-466 
Trap-A (Chromotek), HA-beads (Biotool) or anti-TRIM17 antibody (polyclonal 467 
antibody raised against two human TRIM17 peptides, Eurogentec). For 468 
immunoprecipitation, cell lysates 4 times diluted in buffer B (50 mM Tris-HCl [pH 7.5], 469 
150 mM NaCl and protease inhibitor cocktail) were incubated for 4 h at 4°C with anti-470 
GFP or anti-Flag beads as indicated. The beads were then recovered by 471 
centrifugation and washed four times with lysis buffer B supplemented with 0.5 M 472 
NaCl. Precipitates were then eluted by the addition of 3 × Laemmli sample buffer and 473 
incubation at 95°C for 5 min. Precipitated proteins were separated by 4-12% SDS–474 
PAGE and analyzed by western blot as described above.  475 
 476 
Measurement of BCL2A1 ubiquitination levels 477 
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HEK293T cells were transfected with the indicated plasmids together with His-tagged 478 
ubiquitin. 24h after transfection, cells were treated with 20 μM MG-132 for 6 h prior 479 
cell harvesting. 10% of the cells were lysed in buffer A  containing 1% NP-40 and 480 
used as total lysates. The rest of the cells were homogenized and ubiquitinated 481 
proteins were purified using nickel beads as previously described [29]. Ubiquitinated 482 
proteins and total lysate were resolved by SDS-PAGE and blotted using antibodies 483 
as indicated. 484 
 485 
In situ proximity ligation assay 486 
HuH7 or SK-MEL-28 cells were seeded onto gelatin-coated glass coverslips. When 487 
transfection was performed, cells were transfected with pcDNA-Flag-BCL2A1 for 24 h 488 
or with the corresponding empty plasmid. Then, cells were fixed with 4% 489 
paraformaldehyde for 20 min, washed with PBS and permeabilized with 0.2 % Triton 490 
X-100 in PBS for 10 min, at room temperature. The interaction between endogenous 491 
BCL2A1 or Flag-BCL2A1 and endogenous TRIM28 was detected using the Duolink® 492 
In Situ kit (Sigma), according to the manufacturer’s instructions as previously 493 
described [62], using primary antibodies against BCL2A1 (Millipore, 1:200) or 494 
TRIM28 (Abcam, clone 20C1; 1:1000) or TRIM17 (Abnova, clone 2E11, 1:1000) 495 
Images were analyzed by confocal fluorescence microscopy (Leica SP5) and ImageJ 496 
software. 497 
 498 
sgRNA design and cloning 499 
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Constitutive Cas9 and inducible guide RNA vectors have been described previously 500 
[31]. The MIT CRISPR design software was used for the design of sgRNA 501 
(htpp://crispr.mit.edu). To clone individual sgRNAs, 24-bp oligonucleotide containing 502 
the sgRNA were synthesized (IDT). They included a 4-bp overhang for the forward 503 
(TCCC) and complementary reverse (AAAC) oligos to enable cloning into the Bsmb-I 504 
site of the lentiviral construct FgH1tUTG as previously described [31]. sgRNA 505 
sequences are as follows: TRIM17#1: 5’-CACCTTGGTCAGCAGCCGGT; TRIM17#2: 506 
5’-GGAACTCGCCAGAAAACTGC. To target BCL2A1 we used a sgRNA guide 507 
previously described [32]. Negative control used was targeting murine sequence of 508 
Bim as previously described [31]. 509 
 510 
Viral production, transduction of cell lines and doxycycline treatment 511 
Lentiviral particles were produced by transient transfection of 293T and virus-512 
containing supernatants were collected 48-72 h after transfection and passed 513 
through a 0.45 μm filter as previously described [63]. SK-MEL-28 cells were 514 
transduced by lentiviral particles as previously described [31]. In order to induce 515 
expression of the sgRNA in cell lines, doxycycline hyclate (Sigma #D9891) was 516 
added for 72 h to tissue culture medium at a final concentration of 1 μg/ml. 517 
 518 
Detection of InDels by T7 endonuclease I assay 519 
Genomic DNA was extracted 72 h after doxycycline treatment using QuickExtract 520 
DNA extraction solution (Epicentre). DNA fragment which comprises targeted 521 
sequences by TRIM17 sgRNAs was amplified by PCR (Gotaq, Promega) using the 522 
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following primers: 5’-GAGGCTGTACAGGACGGTTG and 5’-523 
GAAAAGCTTGAGGGGCTCGT. Amplicon was purified, denatured and re-annealed 524 
to allow heteroduplex formation between wild-type DNA and CRISPR/Cas9-mutated 525 
DNA. Product was digested with T7 endonuclease I (NEB) and fragments separated 526 
by electrophoresis on a 2% high resolution agarose gel. 527 
 528 
Cell death assay and flow cytrometric analysis 529 
Cells were seeded at 50x103 cells per well in a 6 well plate, allowed to settle for 24 h, 530 
before treatment with 1 µg/mL Doxycycline hyclate for 72 h to induce sgRNA 531 
expression. Cells were then harvested and seeded at 2x103 cells per well (each 532 
condition in triplicate), in a 96 well plate and allowed to settle for 24 h. Cells were 533 
then treated with either 20 µM PLX4720 or DMSO for 48 h. Cells were harvested and 534 
resuspended in Annexin V binding buffer (0.1 M Hepes (pH 7.4), 1.4 M NaCl, 25 mM 535 
CaCl2) and Annexin V (conjugated to Alexa Fluor 647) and analyzed by flow 536 
cytometry (LSRII, Becton Dickinson).  537 
 538 
Calculation of Specific Induced Apoptosis (SIA) 539 
In order to discriminate the PLX4720 specific induced apoptosis vs spontaneous cell 540 
death due to transfection toxicity in SK-MEL-28 cells, we calculated the percentage of 541 
specific induced apoptosis (% SIA) using the following formula: % SIA = [(PLX4720 542 
induced apoptosis – media only spontaneous apoptosis)/(100 – media only 543 
spontaneous apoptosis)] × 100. 544 
 545 
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Statistical Analysis 546 
Statistical analyses of data sets were performed using GraphPad Prism version 7.00 547 
for MAC OS X, GraphPad Software, La Jolla California USA. Unless indicated, data 548 
are presented as the mean ± SEM. 549 
 550 
Targeted PCR and sequencing of sites of Cas9-induced InDels 551 
Genomic DNA was prepared by resuspending cells into Direct PCR lysis buffer 552 
(Viagen) with proteinase K (Sigma-Aldrich P4850), and incubated with gentle shaking 553 
for 4-6 h followed by heat inactivation at 85˚C for 45 min. Unique primers were 554 
designed to amplify regions flanking the sgRNA binding site (approximately 120 bp in 555 
total), and included sequence overhangs at the 5’ end of the forward and reverse 556 
primers as follows (FWD OH: 5’ GTGACCTATGAACTCAGGAGTC 3’ ; REV OH: 5’ 557 
CTGAGACTTGCACATCGCAGC 3’). The first step PCR cycling conditions were as 558 
follows; 95˚C 2 min (95˚C 30 s, 60˚C 30 s, 72˚C 30 s) x 25 cycles, 72˚C 5 min. PCR 559 
amplicons were individually purified using 1.03 Ampure Beads (Beckman Coulter). 560 
Amplicon size distribution was ascertained using the Agilent Tapestation D1000 561 
protocol. Secondary amplification using overhang sequences and Illumina MISeq 562 
sequencing was done as previously described [31]. 563 
 564 
RNA preparation and real time quantitative RT-PCR 565 
Total RNA was extracted using the RNAqueous® kit (Ambion) and treated with 566 
DNase I from the DNA-free™ kit (Ambion) according to manufacturer's instructions. 567 
RNA was used to perform a two-step reverse-transcription polymerase chain reaction 568 
(RT-PCR) as previously described [53]. 569 
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The sequences of the primers used were as follows: human BCL2A1: Forward 5’-570 
ATGGATAAGGCAAAACGGAGG-3’; Reverse 5’-TATGGAGTGTCCTTTCTGGTAA-571 
3’; human TRIM17: Forward 5’-GACATGGAGTACCTTCGGGA-3’; Reverse 5’-572 
GCAGTCTCCTCTTCTTCCGT-3’; human TRIM28: Forward 5’-573 
AGCTGTGAGGATAATGCCCC-3’; Reverse 5’-GTTCACCATCCCGAGACTTG-3’; 574 
GAPDH Forward 5’-CCATCTTCCAGGAGCGAGAT-3’; Reverse 5’-575 
GGTTCACACCCATGACGAAC-3’. Data were analyzed and relative amounts of 576 
specifically amplified cDNA were calculated with MxPro software (Agilent). Human 577 
GAPDH amplicon was used as a reference. 578 
 579 
In vitro phosphorylation assays 580 
Recombinant full-length human GST-tagged BCL2A1 protein was a gift of Nathalie 581 
Bonnefoy (IRCM, Montpellier). The BH3 peptides sequences used for this study were 582 
the same as previously described [13]. Peptides with free N- and C termini were 583 
synthesized by Genecust (Luxembourg), purified by reverse-phase HPLC. They were 584 
˃90% pure and were dissolved as 1 mM stock solutions in water. BCL2A1-α9 peptide 585 
purification and sequence was previously described [64]. The accession numbers on 586 
which the peptides were based are as follows: hBimL (AAC39594), hPuma 587 
(AAK39542), hBad (NP_004313), hNoxa (NP_066950) and mNoxa (NP_067426). 588 
For in vitro phosphorylation assays, synthetic BCL2A1-α9 peptide (4 pmol), GST-589 
BCL2A1 (400 ng) or GST-BCL2A1 pre-incubated with BH3 peptide (molar ratio 1:10) 590 
for 1 h at 4°C, were incubated for 30 min at 30°C in a total volume of 20 μl kinase 591 
reaction buffer (Biolabs) containing 5 μCi [γ-32P]-ATP in the presence of 100 ng of 592 
recombinant GSK3β kinase (Biolabs). The reaction was stopped by the addition of 593 
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Laemmli buffer. Phosphorylation of peptide or protein was resolved by 4-12% SDS 594 
PAGE (NuPAGE, Invitrogen) and visualized by autoradiography. 595 
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Figure Legends 824 
 825 
Figure 1: TRIM28 binds BCL2A1 at mitochondria. (a) Total protein extracts from 826 
HEK293T cells expressing either GFP-BCL2A1 of control GFP were subjected to 827 
immunoprecipitation using anti-GFP antibody. Immunoprecipitates were separated by 828 
SDS-PAGE and visualized using colloidal Coomassie-staining. (b) GFP-tagged 829 
BCL2A1, or its phosphorylation-defective and unstable mutant 830 
BCL2A1(S152A,T156A), were co-expressed with HA-tagged TRIM28 in HEK293T 831 
cells as indicated. GFP-BCL2A1 (upper panel) or HA-TRIM28 (lower panel) was 832 
immunoprecipitated with GFP-trap beads or HA-beads respectively. HA-TRIM28 and 833 
GFP-BCL2A1 were detected in immunoprecipitates and input samples by western-834 
blot using appropriate antibodies. (*) shows IgG heavy chains. . (c) In situ proximity 835 
ligation assay (PLA) was performed in SK-MEL-28 melanoma cells expressing a 836 
DOX-inducible sgRNA targeting BCL2A1 (see Fig. 6), using anti-TRIM28 and anti-837 
BCL2A1 antibodies. Each green bright spot indicates the very close proximity of the 838 
two endogenous proteins. A negative control was obtained by inducing the BCL2A1 839 
sgRNA to efficiently induce InDels in the BCL2A1 locus and prevent BCL2A1 840 
expression (see Fig. S4b). Scale bars, 10 μm. (d) PLA was performed in HuH7 841 
hepatocarcinoma cells using anti-BCL2A1 and anti-TRIM28 antibodies. Mitochondria 842 
were imaged following transfection of the mitoDsRed plasmid encoding fluorescent 843 
DsRed2 fused to the mitochondrial targeting sequence from subunit VIII of human 844 
cytochrome c oxidase. A negative control was obtained by omitting the anti-BCL2A1 845 
antibody. Scale bars, 10 μm. 846 
38 
Figure 2: TRIM28 regulates the ubiquitination and degradation of BCL2A1. (a) 847 
HEK293T cells were transfected with GFP-BCL2A1, Myc-TRIM28 and MAGEC2-HA 848 
constructs as indicated, together with His-tagged ubiquitin (Ub-His) for 18 h. Then 849 
cells were incubated with MG132 for 6 h. Total ubiquitinated proteins were purified 850 
using nickel beads and analyzed by western blot using anti-GFP antibody to detect 851 
poly-ubiquitinated forms of BCL2A1. Initial total lysates were analyzed for the 852 
expression of the different proteins by immunoblot. (b) HEK293T cells were first 853 
transfected with two different siRNAs to inhibit TRIM28 expression. Twenty-four 854 
hours later, cells were transfected with GFP-BCL2A1 and Ub-His for one additional 855 
day. Then, cells were treated and cell lysates were analyzed. (c) SK-MEL-28 cells 856 
were transfected with two different siRNAs for two consecutive days to inhibit 857 
TRIM28 expression. Cells were collected 48 h after the first siRNA transfection. The 858 
efficiency of TRIM28 silencing and its effect on the protein level of endogenous 859 
BCL2A1 were assessed by immunoblot. (d) HEK293T cells were co-transfected with 860 
Flag-tagged BCL2A1 and Myc-tagged TRIM28 or an inactive RING mutant C65/68A 861 
of TRIM28 for 24 h. Transfected cells were treated with the protein synthesis inhibitor 862 
cycloheximide (CHX, 10 μg/ml) for increasing times as indicated. Total protein 863 
extracts were analyzed by immunoblot. The protein level of Flag-BCLA1 was followed 864 
with time using anti-Flag antibody in order to measure its half-life. Anti-Myc antibody 865 
was used to verify equal expression of TRIM28 and anti-tubulin antibody to assess 866 
equal loading. Data shown are representative of three independent experiments. 867 
BCL2A1 protein level was quantified by densitometry and was expressed as a 868 
percentage of the value measured at time zero for each of the three conditions. 869 
 870 
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Figure 3: TRIM17 induces the stabilization of BCL2A1 protein. (a) HEK293Tcells 871 
were transfected with GFP-tagged BCL2A1 and TRIM17-Flag as indicated. Cell 872 
lysates were subjected to immunoprecipitation with GFP-Trap beads (left) or Flag-873 
beads (right), and the presence of TRIM17 or BCL2A1 was detected by western blot 874 
using anti-Flag or anti-GFP antibodies respectively (*) shows IgG heavy chains (b) 875 
SK-MEL-28 protein extract was subjected to immunoprecipitation using an anti-876 
TRIM17 antibody or the corresponding pre-immune serum as an negative control, as 877 
indicated. BCL2A1 and TRIM17 proteins were detected in the immunoprecipitate by 878 
western blot using specific antibodies. (c) HEK293T cells were transfected with 879 
FLAG-BCL2A1 and increasing amounts of TRIM17-GFP vectors for 48 h. Total 880 
protein extracts were subjected to immunoblot analyses using the indicated 881 
antibodies. (d) HEK293T cells were transfected with Flag-tagged BCL2A1 in the 882 
presence or the absence of GFP-tagged TRIM17 for 24 h. Transfected cells were 883 
treated with cycloheximide (CHX, 10 μg/ml) for the indicated time periods. Total 884 
protein extracts were analyzed by immunoblot. The protein level of Flag-BCLA1 was 885 
followed using anti-Flag antibody. Anti-GFP antibody was used to verify equal 886 
expression of TRIM17 and anti-tubulin antibody to assess equal loading. Data shown 887 
are representative of three independent experiments. BCL2A1 protein level was 888 
quantified by densitometry and was expressed as a percentage of the value 889 
measured at time zero for each of the two conditions. 890 
 891 
Figure 4: TRIM17 impairs TRIM28/BCL2A1 interaction and prevents TRIM28-892 
mediated ubiquitination of BCL2A1. (a) HEK293T cells were transfected with the 893 
indicated plasmids and cell lysates were subjected to immunoprecipitation with GFP-894 
trap beads. Immunoprecipitates were analyzed by western blot using anti-HA and 895 
40 
anti-GFP antibodies. (b) PLA was performed in SK-MEL-28 cells expressing a DOX-896 
inducible sgRNA against TRIM17 (see Fig. 6), using anti-TRIM17 and anti-TRIM28 897 
antibodies. Each green bright spot indicates the very close proximity of the two 898 
endogenous proteins. A negative control was obtained by depleting TRIM17 using 899 
DOX treatment (see Fig. S4b), scale bars, 10 μm. (c) HEK293T cells were 900 
transfected with GFP-BCL2A1, its labile form BCL2A1(S152A, T156A), Flag-TRIM17 901 
and TRIM28-HA plasmids as indicated. Cell lysates were subjected to 902 
immunoprecipitation with anti-GFP antibody to pull down BCL2A1, and the presence 903 
of TRIM17 and TRIM28 in the immunoprecipitates was subsequently detected using 904 
anti-HA or anti-Flag antibodies. (d) HEK293T cells were transfected with the 905 
indicated plasmids in the presence or the absence of His-ubiquitin. Cells were treated 906 
with MG132 for 6 h. Total ubiquitinated proteins were purified using nickel beads and 907 
analyzed by western blot using anti-GFP antibody to detect poly-ubiquitinated forms 908 
of BCL2A1. Initial total lysates were analyzed for the expression of the different 909 
proteins by immunoblot. (e) Working model: the three proteins interact with each 910 
other (double arrows represent physical interactions); TRIM28 mediates BCL2A1 911 
poly-ubiquitination; TRIM17 inhibits TRIM28-mediated ubiquitination of BCL2A1 by 912 
preventing the interaction between the E3 ubiquitin-ligase and its substrate.  913 
 914 
Figure 5: TRIM17 and TRIM28 in BCL2A1-dependent chemoresistant melanoma 915 
cells. (a) Total RNA was extracted from SK-MEL-5 and SK-MEL-28 melanoma cells 916 
and mRNA levels of indicated genes were estimated by quantitative RT-PCR. (b) SK-917 
MEL-28 cells were transfected with a control siRNA (siLUC) or with a specific siRNA 918 
against BCL2A1 for 24 h. Total RNAs were collected and the mRNA levels of 919 
BCL2A1 were estimated by quantitative RT-PCR. The data are the means ± SD of 920 
41 
triplicate samples from a representative experiment. (c) SK-MEL-28 cells were 921 
transfected with a control siRNA (siLUC) or with a specific siRNA against BCL2A1 for 922 
24 h. Then, cells were treated with 20 μM PLX4720 for 24 h and apoptosis was 923 
estimated by flow cytometry using AnnexinV staining. (d) SK-MEL-28 cells were 924 
transfected with GFP or GFP-tagged TRIM proteins, as indicated, for 24 h. Total 925 
protein lysates were analyzed by western blot for the expression of endogenous 926 
BCL2A1 and overexpressed proteins. Note that a part of SK-MEL-28 cells was not 927 
transfected and thus BCL2A1 variations were certainly underestimated. (e) SK-MEL-928 
28 cells were transfected with GFP-tagged TRIM28 or TRIM28(C65A/C68A) for 24 h 929 
and subsequently treated with 20 μM PLX4720 for 24 h. Apoptosis was estimated in 930 
the GFP-positive cell population by flow cytometry using AnnexinV (APC) staining. 931 
Data are presented as % of specific induced apoptosis (SIA, see Methods) and are 932 
the means ± SEM of four independent experiments. *** p=0.0001 significantly 933 
different from GFP-transfected cells, ns p=0.1025 non significantly different from 934 
GFP-transfected cells (one way ANOVA followed by Dunnett’s multiple comparison 935 
test). (f) SK-MEL-28 cells were treated or not (NT) with 20 μM PLX4720 for 24 h. 936 
Total RNA was extracted and mRNA level of TRIM17 was assessed by quantitative 937 
RT-PCR. (g) SK-MEL-28 cells were treated or not (NT) with 20 μM PLX4720 for 24 h 938 
and 48 h. BCL2A1 protein level was assessed by immunoblot. 939 
 940 
Figure 6: TRIM17 invalidation induces BCL2A1 degradation and sensitizes 941 
melanoma cells to BRAF targeted therapy. (a) Method outline depicting generation 942 
of TRIM17-depleted SK-MEL-28 cells by inducible CRISPR/Cas9 method and 943 
workflow of subsequent steps of analysis. (b) SK-MEL-28 cells expressing Cas9 and 944 
inducible sgRNAs against TRIM17 were treated for 72 h with 1 μg/ml doxycycline. 945 
42 
Genomic DNA of cells was amplified by PCR, around the Cas9 cleavage sites 946 
targeted by the two sgTRIM17, and PCR products were analyzed by a T7 947 
Endonuclease I assay. The presence of InDels was visualized by the digestion of the 948 
PCR products at the Cas9 cleavage sites by T7EI. (c) PLA was performed in SK-949 
MEL-28 cells expressing DOX-inducible sgRNA against TRIM17, using anti-TRIM28 950 
and anti-BCL2A1 antibodies. Note that the number of green bright spots indicating 951 
the very close proximity between endogenous TRIM28 and BCL2A1 proteins 952 
increases when expression of endogenous TRIM17 is inhibited by doxycycline 953 
treatment. Negative control was obtained by omitting the anti-BCL2A1 antibody. 954 
Scale bars, 10 μm. (d) The protein level of endogenous BCL2A1 was assessed by 955 
immunoblot using anti-BCL2A1 antibody in total protein extracts from non-transduced 956 
SK-MEL-28 cells left untreated or treated with 20 μM MG132 for 6 h, or from 957 
transduced cells expressing Cas9 alone or Cas9 together with inducible sgRNAs 958 
against BCL2A1 or mouse bim (negative control) and treated or not with 1 μg/ml 959 
doxycycline for 72h, as indicated. (e) Two sgRNAs against TRIM17 were induced in 960 
SK-MEL-28 cells by doxycycline treatment for 72 h and protein level of endogenous 961 
BCL2A1 was assessed by immunoblot using anti-BCL2A1 antibody. (f) SK-MEL-28 962 
cells expressing Cas9 and the indicated sgRNAs were treated with 1 μg/ml 963 
doxycycline for 72 h and subsequently treated with 20 μM PLX4720 (or DMSO 964 
control) for 48 h. PLX4720 specific induced apoptosis (SIA) was assessed by 965 
annexin V staining and flow cytometry. Data are the means ± SEM of three 966 
independent experiments. **** p<0.0001; ** p=0.0093 (sgTRIM17#1) and p=0.0032 967 
(sgTRIM17#2) significantly different from negative control (two way ANOVA followed 968 
by Sidak’s multiple comparison test). 969 
 970 
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Figure 7: GSK3 phosphorylates BCL2A1 in vitro and is involved in BCL2A1 971 
stabilization in cells. (a) NetPhosK 1.0 software was used to predict 972 
phosphorylation sites of alpha9 helix of BCL2A1 and identified Ser152 residue as a 973 
putative phosphorylation site for GSK3. (b) A synthetic peptide derived from α9 helix 974 
of BCL2A1 was incubated with recombinant GSK3 in the presence of [γ-32P]-ATP. 975 
The reaction mix was separated by SDS-PAGE and radiolabeled phosphate 976 
incorporation was detected by autoradiography. * indicates auto-phosphorylated 977 
recombinant GSK3. (c) Purified GST-BCL2A1 full-length recombinant protein was 978 
incubated with indicated synthetic BH3 peptides derived from indicated BH3 proteins 979 
for 2 h at 4°C. In vitro phosphorylation has subsequently carried out by introducing 980 
recombinant GSK3 and [γ-32P]-ATP in the reaction. The protein mix was resolved by 981 
SDS-PAGE and gel was then analyzed by autoradiography. * indicates auto-982 
phosphorylated recombinant GSK3 which migrates approximately at the same level 983 
as phosphorylated BCL2A1. (d) FL5.12 cells stably expressing GFP-BCL2A1 were 984 
maintained in the presence of IL-3, or deprived of IL-3, in the presence or the 985 
absence of GSK3β I-VIII inhibitor for 4 h. Then, cycloheximide (CHX) was added to 986 
the respective culture media for the indicated time periods. Total protein extracts 987 
were analyzed by immunoblot. The protein level of GFP-BCLA1 was followed by 988 
using anti-GFP antibody. Anti-tubulin antibody was used to assess equal loading. 989 
Data shown are representative of three independent experiments. BCL2A1 protein 990 
level was quantified by densitometry and was expressed as the percentage of the 991 
value measured at time zero for each of the three conditions. (e) FL5.12 cells were 992 
cultured in the presence or the absence of IL-3 and endogenous GSK3 activation 993 
was assessed by estimating GSK3 dephosphorylation at Ser9 using anti Phospho 994 
Ser9 GSK3 antibody. 995 







